Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and the hormone receptor status of the tumor. HER2 ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

Enhertu (trastuzumab deruxtecan), in combination with pertuzumab, shows promise as a new first-line treatment for ...

Outside of insurance, your treatment can still be expensive. Meet with your hospital’s social worker and use their resources to map out a plan.

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...

In this manuscript, Hua et al. proposed SLC7A11, a protein facilitating cellular cystine uptake, as a potential target for the treatment of trastuzumab resistant HER2 positive breast cancer. If this ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...

Brain metastasis is emerging as the most serious concern for breast cancer patients. HER2-positive breast cancer is more prone to undergo brain metastasis than other subtypes; notably, there has been ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...